NASDAQ:GRPH Graphite Bio (GRPH) Stock Price, News & Analysis → A.I. is a Tidal Wave - Here’s What to Buy (From Chaikin Analytics) (Ad) Free GRPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.05▼$3.2350-Day Range$3.18▼$26.1152-Week Range$2.01▼$4.26Volume328,300 shsAverage Volume282,405 shsMarket Capitalization$185.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Graphite Bio alerts: Email Address Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. About Graphite Bio Stock (NASDAQ:GRPH)Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.Read More Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. GRPH Stock News HeadlinesMarch 21, 2024 | finance.yahoo.comLENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate ProgressMarch 15, 2024 | finance.yahoo.comGRPH Mar 2024 5.000 putMay 2, 2024 | Weiss Ratings (Ad)Protect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …March 15, 2024 | seekingalpha.comVERI, STI and VERB among mid-day moversMarch 15, 2024 | finance.yahoo.comGRPH Mar 2024 7.500 callMarch 14, 2024 | finance.yahoo.comGraphite Bio, Inc. (GRPH)March 10, 2024 | marketwatch.comGraphite Bio to Pay Special Dividend Linked to Lenz Therapeutics MergerMarch 8, 2024 | au.investing.comGraphite Bio announces $1.03 per share special dividendMay 2, 2024 | Weiss Ratings (Ad)Protect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …March 8, 2024 | msn.comGraphite Bio declares special $1.03 dividendMarch 8, 2024 | businesswire.comGraphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz TherapeuticsFebruary 27, 2024 | businesswire.comGRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPHFebruary 2, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Graphite Bio, Inc. (GRPH)December 25, 2023 | seekingalpha.comGraphite Bio: Reverse Merger Leading Into Big Special Dividend And Q2 Phase 3 TrialNovember 27, 2023 | msn.comGraphite Bio (GRPH) Price Target Increased by 40.00% to 7.14November 17, 2023 | businesswire.comGRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPHNovember 17, 2023 | businesswire.comGRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPHNovember 16, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ TherapeuticsNovember 16, 2023 | bizjournals.comShattered dream of sickle cell disease cure to end in reverse merger for Peninsula biotechNovember 16, 2023 | finance.yahoo.comWhat Makes Graphite Bio, Inc. (GRPH) a New Buy StockNovember 15, 2023 | benzinga.comGRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to ShareholdersNovember 15, 2023 | markets.businessinsider.comGraphite Bio To Merge With LENZ Therapeutics; Stock Down In Pre-marketNovember 15, 2023 | finance.yahoo.comLENZ Therapeutics and Graphite Bio Announce Merger AgreementNovember 9, 2023 | morningstar.comGraphite Bio Inc GRPHNovember 1, 2023 | msn.comGraphite Bio (GRPH) Price Target Increased by 25.00% to 5.10October 5, 2023 | msn.comGraphite Bio (GRPH) Price Target Increased by 11.11% to 4.08June 23, 2023 | seekingalpha.comGraphite Bio CFO resigns to pursue other opportunitiesSee More Headlines Receive GRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2023Ex-Dividend for 3/21 Dividend3/15/2024Dividend Payable3/21/2024Today5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GRPH CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.12% Return on Assets-27.96% Debt Debt-to-Equity RatioN/A Current Ratio39.20 Quick Ratio39.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book1.01Miscellaneous Outstanding Shares58,240,000Free Float35,874,000Market Cap$185.20 million OptionableNot Optionable Beta0.20 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Matthew Porteus M.D. (Age 58)Ph.D., Academic Founder & Director Comp: $110kStephanie YaoVice President of Communications & Investor RelationsDr. Christine Garrett P.M.P. (Age 53)Ph.D., Chief Strategy Officer Key CompetitorsZura BioNASDAQ:ZURAInnate PharmaNASDAQ:IPHAX4 PharmaceuticalsNASDAQ:XFORCentury TherapeuticsNASDAQ:IPSCAcumen PharmaceuticalsNASDAQ:ABOSView All CompetitorsInstitutional OwnershipSectoral Asset Management Inc.Bought 441,829 shares on 2/14/2024Ownership: 0.762%BML Capital Management LLCBought 447,416 shares on 2/2/2024Ownership: 0.771%View All Institutional Transactions GRPH Stock Analysis - Frequently Asked Questions How were Graphite Bio's earnings last quarter? Graphite Bio, Inc. (NASDAQ:GRPH) issued its earnings results on Monday, March, 20th. The company reported ($3.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.43) by $0.35. How often does Graphite Bio pay dividends? What is the dividend yield for Graphite Bio? Graphite Bio declared a dividend on Friday, March 15th. Stockholders of record on Monday, March 18th will be paid a dividend of $7.21 per share on Thursday, March 21st. This represents a dividend yield of 28.93%. The ex-dividend date is Friday, March 15th. Read our dividend analysis for GRPH. When did Graphite Bio's stock split? Graphite Bio's stock reverse split on Friday, March 22nd 2024. The 1-7 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. When did Graphite Bio IPO? Graphite Bio (GRPH) raised $224 million in an IPO on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share. This page (NASDAQ:GRPH) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportUrgent dollar warningStansberry ResearchYour bank is lying to you.MyBankTrackerDollar CancelledLear Capital Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graphite Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
